Please login to the form below

Not currently logged in
Email:
Password:

ataluren

This page shows the latest ataluren news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer unimpressed with PTC’s Translarna

FDA reviewer unimpressed with PTC’s Translarna

The dossier for Translarna (ataluren) has already been in front of the FDA twice and rejected both times, and analysts from Credit Suisse and JP Morgan both suggested that the chances

Latest news

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2014 Pharma deals during January 2014

    In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m. ... Ataluren was in clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics